Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

1 day ago

Vistagen Inc. (NASDAQ:VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per …

Read Entire Article

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Related

Inflation Cools and Stocks Rise, So Why Is Bitcoin Still Flo...

Acting CFTC chair Caroline Pham to join MoonPay: CNBC Crypto...

Former NRL Trent Merrin star avoids conviction over $140k cr...

ETH And SOL Struggling To Stay Above Water

Bitcoin Whipsaws From $89,000 To $85,000, Liquidates $120M: ...

As Robinhood Moves Into Sports Betting, Should You Buy, Sell...

Fed rescinds Biden-era crypto guidance

Report: NYSE Owner ICE Eyes Investment in Crypto Payments Fi...

Popular

The clearest signal of a dollar collapse

BITCOIN WHALES KNOW SOMETHING!

Massie Takes On the War Machine — And Trump and Rubio are Fu...

Bitcoin, Ethereum, XRP, Dogecoin Decline Ahead Of Consumer I...

JGBs Mixed on Possible Position Adjustments

Putin just destroyed Europe's war lies with this one move | ...